Ranolazine en es it fr

Ranolazine Brand names, Ranolazine Analogs

Ranolazine Brand Names Mixture

  • No information avaliable

Ranolazine Chemical_Formula


Ranolazine RX_link

No information avaliable

Ranolazine fda sheet

Ranolazine FDA

Ranolazine msds (material safety sheet)

Ranolazine Synthesis Reference

No information avaliable

Ranolazine Molecular Weight

427.537 g/mol

Ranolazine Melting Point

No information avaliable

Ranolazine H2O Solubility

Very slightly soluble

Ranolazine State


Ranolazine LogP


Ranolazine Dosage Forms

Tablets (extended release - 500 mg)

Ranolazine Indication

For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates.

Ranolazine Pharmacology

Ranolazine has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. It is the first new anti-anginal developed in over 20 years.

Ranolazine Absorption

Absorption is highly variable. After oral administration of ranolazine as a solution, 73% of the dose is systemically available as ranolazine or metabolites. The bioavailability of oral ranolazine relative to that from a solution is 76%.

Ranolazine side effects and Toxicity

In the event of overdose, the expected symptoms would be dizziness, nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss of consciousness may develop.

Ranolazine Patient Information

AMITIZA™ may cause nausea. If this occurs, concomitant administration of food with AMITIZA™ may reduce symptoms of nausea. AMITIZA™ should not be administered to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. If the diarrhea becomes severe consult your physician.

Ranolazine Organisms Affected

Humans and other mammals